Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydralazine and Magnesium Valproate for Refractory Solid Tumors
NCT00404508Phase 2Completed
- Sponsor
- Instituto Nacional de Cancerología
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydralazine and magnesium valproate in solid tumor, sponsored by Instituto Nacional de Cancerología. Primary endpoints: Clinical benefit (complete response, partial response and stable disease) and Safety. Started Sep 2005; status: completed.
02
Drugs
hydralazinemagnesium valproate
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT00404508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00404508.